Keep tabs on your favorite ETFs with a personalized weekly tracker. Create a Watchlist now →
CANCvsSBIOETF Comparison
Tema Oncology ETF (CANC) and ALPS Medical Breakthroughs ETF (SBIO) belong to the same industry segment: Tomorrow's Treatments. CANC's top 3 sector exposures are and Health Care. CANC is more expensive with a Total Expense Ratio (TER) of 0.99%, versus 0.5% for SBIO. CANC is up 4.1% year-to-date (YTD) with +$41M in YTD flows. SBIO performs worse with -1.76% YTD performance, and +$9M in YTD flows. Run a side-by-side ETF comparison of CANC and SBIO below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
CANC vs SBIO performance and flow charts
Performance
Cumulative Flows
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | CANC SBIO | -0.94%+0.04% | +4.18%-1.89% | +4.10%-1.76% | +43.76%+62.14% | n/a+85.68% | n/a-4.45% |
| Flows | CANC SBIO | +$12M+$1M | +$49M+$19M | +$41M+$9M | +$63M+$261K | --$14M | --$80M |
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | CANC SBIO | +23.29%+29.80% | +25.13%+31.95% | n/a+29.87% | n/a+33.63% |
| Max drawdown | CANC SBIO | -4.68%-9.46% | -17.26%-24.01% | n/a-42.12% | n/a-57.02% |
| Max drawdown duration | CANC SBIO | 16d49d | 80d80d | n/a331d | n/a1744d |
CANC | SBIO | |
Last sale 3/13/2026 at 6:45 PM | $36.15 | $49.79 |
| Previous close 03/12/2026 | $36.33 | $50.18 |
| Consolidated volume 03/12/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Create an account to view replication metrics
CANC | SBIO | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
CANC | SBIO | |
|---|---|---|
| Last price | $36.15 | $49.79 |
| 1D performance | -0.50% | -0.78% |
| AuM | $161.18 M | $134.37 M |
| E/R | 0.99% | 0.5% |
Countries
Sectors
Diversification
Total weight of top 15 holdings out of 15
Top 15 holdings
How have the CANC and SBIO ETFs performed in 2026?
As of March 12, 2026, CANC is up 4.1% year-to-date (YTD), while SBIO has lost -1.76%. That puts CANC better performer ahead so far this year.
Which ETF is attracting more investor money: CANC or SBIO?
Year-to-date, the CANC ETF saw +$41M in flows, compared to +$9M for SBIO.
Which ETF is more volatile: CANC or SBIO?
Over the past year, CANC had a volatility of 25.13%, while SBIO experienced 31.95%.
Which ETF is bigger: CANC or SBIO?
As of March 12, 2026, CANC holds $161.18 M in assets under management (AUM), while SBIO manages $134.37 M.
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
Two biotech ETFs to watch for the rest of 2022 and beyond
Active Trader Report: Use of Leveraged & Inverse ETFs Way Up
Direxion partnered with Compound Insights and Vanda to explore what’s driving the evolution of active trading — and how active traders are using leveraged and inverse funds across equities, single stocks, commodities, and volatility.
